CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ProbioticWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug303 Control Wiki 0.35

Correlated MeSH Terms (8)

Name (Synonyms) Correlation
D008173 Lung Diseases, Obstructive NIH 0.32
D008171 Lung Diseases, NIH 0.29
D002318 Cardiovascular Diseases NIH 0.18
D011024 Pneumonia, Viral NIH 0.10
D011014 Pneumonia NIH 0.05
D007239 Infection NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (4)

Name (Synonyms) Correlation
HP:0006536 Obstructive lung disease HPO 0.32
HP:0002088 Abnormal lung morphology HPO 0.29
HP:0001626 Abnormality of the cardiovascular system HPO 0.18
HP:0002090 Pneumonia HPO 0.05

There are 2 clinical trials

Clinical Trials

1 Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19

The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study

NCT04366180 Covid-19 Dietary Supplement: Probiotic Dietary Supplement: Control

Primary Outcomes

Description: The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test

Measure: Incidence of SARS CoV-2 infection in healthcare workers

Time: 8 weeks

Secondary Outcomes

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19

Measure: Incidence of hospital admissions caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19

Measure: Incidence of ICU admissions caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19

Measure: Incidence of pneumonia caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19

Measure: Incidence of oxygen support requirement caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19

Measure: Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature > 37.5 ºC during the course of the disease

Measure: Days with body's temperature > 37.5 ºC

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease

Measure: Days with cough

Time: 8 weeks

Description: In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease

Measure: Days with fatigue

Time: 8 weeks

Description: Use of drugs (dosis and duration of the treatment) for Covid-19 treatment

Measure: Medical treatment

Time: 8 weeks

2 The Intestinal Microbiota as a Therapeutic Target in Hospitalized Patients With COVID-19 Infection

A prospective case-control pilot study to evaluate the possible effect of a probiotic mixture in the improvement of symptoms, the reduction in the number of days of hospitalization and the increase in the percentage of patients with negative PCR after infection with the coronavirus SARS-CoV-2.

NCT04390477 COVID-19 Coronavirus Infecti Coronavirus Infection Dietary Supplement: Probiotic
MeSH:Infection Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Percentage of patients with discharge to ICU.

Measure: Cases with discharge to ICU.

Time: 30-days

Secondary Outcomes

Description: Percentage of patients with home discharge.

Measure: Patients with home discharge.

Time: 30-days

Description: Percentage of deaths.

Measure: Mortality.

Time: 30-days

Description: Number of adverse events that occur during the treatment period, attributable or not to the intervention product.

Measure: Treatment safety assessed by number of adverse events.

Time: 30-days

Description: Number of new cases of positive SARS-Cov-2 infection by PCR analysis.

Measure: New cases of SARS-Cov-2 infection among healthcare personnel caring for the patients.

Time: 30-days

Description: Percentage of patients with negative PCR for SARS-CoV-2.

Measure: Patients with negative PCR result for SARS-CoV-2 infection.

Time: 30-days

No related HPO nodes (Using clinical trials)